EP0268989A1 — Imidazopyridine compounds and processes for preparation thereof
Assigned to Fujisawa Pharmaceutical Co Ltd · Expires 1988-06-01 · 38y expired
What this patent protects
An imidazopyridine compound of the formula : wherein R' is lower alkynyl, lower alkynyloxy(lower)alkyl or N,N-di(lower)alkylamino(lower)alkynyl, R 2 is lower alkyl, R 3 is ar(lower)alkyl substituted by one or more substituent(s) selected from cyano, trihalo(lower)al…
USPTO Abstract
An imidazopyridine compound of the formula : wherein R' is lower alkynyl, lower alkynyloxy(lower)alkyl or N,N-di(lower)alkylamino(lower)alkynyl, R 2 is lower alkyl, R 3 is ar(lower)alkyl substituted by one or more substituent(s) selected from cyano, trihalo(lower)alkyl, carbamoyl, protected amino, carboxy, protected carboxy, hydroxy, hydroxy(lower)alkyl, protected hydroxy-(lower)alkyl, protected hydroxy and protected amino(lower)alkyl or ar(lower)alkyl substituted by lower alkyl and one additional substituent selected from hydroxy(lower)alkyl, amino, N-lower alkyl-N-protected amino, protected amino and lower alkylamino, and R 4 is hydrogen or lower alkyl, and a pharmaceutically acceptable salt thereof, processes for their preparation and pharmaceutical compositions comprising them. The invention also comprises intermediates of the formula and of the formula
Drugs covered by this patent
- Oxbryta (voxelotor) · Global Blood Theraps
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.